Prescribers remain cautious about substituting generic drugs for narrow therapeutic index (NTI) medications like warfarin and levothyroxine due to risks of instability. While the FDA affirms generic safety, real-world data shows prescribers prioritize patient stability, leading to state-level restrictions and ongoing debate over substitution practices.